| abstract |
6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-pro Panyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidine-2( Provided are crystalline and amorphous forms of 1H)-one, as well as solid state forms of these forms, pharmaceutical compositions, and methods of treating diseases mediated by KRAS G12C inhibition. |